

Hemovigilance Module Adverse Reaction Post Transfusion Purpura

*Required for saving	•
*Facility ID#: NH	ISN Adverse Reaction #:
Patient Information	
*Patient ID: Social Security #:	
Last Name:	First Name: Middle Name:
Ethnicity 🗌 Hispanic or Lat	ino 🗌 Not Hispanic or Not Latino
Race American India	n/Alaska Native 🗌 Asian 🔤 Black or African American
	n/Other Pacific Islander 🛛 🗌 White
•	$ \square$ B- \square B+ \square AB- \square AB+ \square O- \square O+ \square Blood type not done
	ABO / Rh +I Transitional ABO / Rh -I Transitional ABO / Transitional RhGroup B/Transitional RhGroup O/Transitional RhGroup AB/Transitional Rh
Patient Medical History	
List the patient's admitting of	liagnosis. (Use ICD-10 Diagnostic codes/descriptions)
Code:	Description:
Code:	Description:
Code:	Description:
List the patient's underlying	indication for transfusion. (Use ICD-10 Diagnostic codes/descriptions)
Code:	Description:
Code:	Description:
Code:	Description:
List the patient's comorbid or reaction. <i>(Use ICD-10 Diag</i>)	conditions at the time of the transfusion related to the adverseUNKNOWNnostic codes/descriptions)NONE
Code:	Description:
Code:	Description:
Code:	Description:
of any individual or institution is coll stated, and will not otherwise be dis	oluntarily provided information obtained in this surveillance system that would permit identification ected with a guarantee that it will be held in strict confidence, will be used only for the purposes closed or released without the consent of the individual, or the institution in accordance with Public Health Service Act (42 USC 242b, 242k, and 242m(d)).
reviewing instructions, searching ex collection of information. An agenc unless it displays a currently valid C	ction of information is estimated to average 20 minutes per response, including the time for isting data sources, gathering and maintaining the data needed, and completing and reviewing the y may not conduct or sponsor, and a person is not required to respond to a collection of information MB control number. Send comments regarding this burden estimate or any other aspect of this uggestions for reducing this burden to CDC, Reports Clearance Officer, 1600 Clifton Rd., MS D-74, 20-0666).

NHSN NATIONAL HEALTHCARE SAFETY NETWORK	Exp	Form Approved B No. 0920-0666 p. Date: 01/31/25 ww.cdc.gov/nhsn
	edical procedure including past procedures and procedures to be	NKNOWN ONE
Code:	Description:	
Code:	Description:	
Code:	Description:	
Additional Information		
Transfusion History		
Has the patient received a p	revious transfusion?	٧N
Blood Product:	WB 🗌 RBC 🗌 Platelet 🗌 Plasma 🗌 Cryoprecipitate 🗌 G	Granulocyte
Date of Transfusion:		
Was the patient's adverse	reaction transfusion-related?	
	about the transfusion adverse reaction.	
	se reaction:	
		NKNOWN
	/	
Reaction Details		
	/ *Time reaction occurred:: Time unknow	
*Facility location where patier	nt was transfused:	· · · · · · · · ·
Is this reaction associated with	an incident? Ves No. If Ves Incident #:	
Is this reaction associated with a	an incident? Yes No If Yes, Incident #:	
Investigation Results		
Investigation Results * Post transfusion purpura		
Investigation Results * Post transfusion purpura *Case Definition	a (PTP)	
Investigation Results * Post transfusion purpura *Case Definition Check all that occurred af	a (PTP) fter cessation of transfusion : patient directed against HPA or other platelet specific antigen detected at	
Investigation Results * Post transfusion purpura *Case Definition Check all that occurred af Alloantibodies in the p development of thron	a (PTP) fter cessation of transfusion : patient directed against HPA or other platelet specific antigen detected at	
Investigation Results * Post transfusion purpura *Case Definition Check all that occurred af Alloantibodies in the p development of throm Thrombocytopenia (i.e.	a (PTP) fter cessation of transfusion : patient directed against HPA or other platelet specific antigen detected at mbocytopenia.	
Investigation Results * Post transfusion purpura *Case Definition Check all that occurred af Alloantibodies in the p development of throm Thrombocytopenia (i.e.	a (PTP) fter cessation of transfusion : patient directed against HPA or other platelet specific antigen detected at mbocytopenia. e., decrease in platelets to less than 20% of pre-transfusion count).	
Investigation Results * Post transfusion purpura *Case Definition Check all that occurred af Alloantibodies in the p development of throm Thrombocytopenia (i.d Decrease in platelets Check all that apply: PTP is suspected, but	a (PTP) fter cessation of transfusion : patient directed against HPA or other platelet specific antigen detected at mbocytopenia. e., decrease in platelets to less than 20% of pre-transfusion count). to levels between 20% and 80% of pre-transfusion count. tt laboratory findings and/or information are not sufficient. NOTE: For exar platelet count to less than 80% of pre-transfusion count but HPA antibodi	or after mple, the
Investigation Results * Post transfusion purpura *Case Definition Check all that occurred af Alloantibodies in the p development of thron Thrombocytopenia (i.d Decrease in platelets Check all that apply: PTP is suspected, bur patient has a drop in	a (PTP) fter cessation of transfusion : patient directed against HPA or other platelet specific antigen detected at mbocytopenia. e., decrease in platelets to less than 20% of pre-transfusion count). to levels between 20% and 80% of pre-transfusion count. t laboratory findings and/or information are not sufficient. NOTE: For exar platelet count to less than 80% of pre-transfusion count but HPA antibodi ive.	or after mple, the
Investigation Results * Post transfusion purpura *Case Definition Check all that occurred af Alloantibodies in the p development of throu Thrombocytopenia (i.d Decrease in platelets Check all that apply: PTP is suspected, bur patient has a drop in tested or were negati	a (PTP) fter cessation of transfusion : patient directed against HPA or other platelet specific antigen detected at mbocytopenia. e., decrease in platelets to less than 20% of pre-transfusion count). to levels between 20% and 80% of pre-transfusion count. t laboratory findings and/or information are not sufficient. NOTE: For exar platelet count to less than 80% of pre-transfusion count but HPA antibodi ive.	or after mple, the ies were not
Investigation Results * Post transfusion purpura *Case Definition Check all that occurred af Alloantibodies in the p development of throm Thrombocytopenia (i.d Decrease in platelets Check all that apply: PTP is suspected, bur patient has a drop in tested or were negati Other signs and symptoms: (c	fter cessation of transfusion : patient directed against HPA or other platelet specific antigen detected at mbocytopenia. e., decrease in platelets to less than 20% of pre-transfusion count). to levels between 20% and 80% of pre-transfusion count. t laboratory findings and/or information are not sufficient. NOTE: For exar platelet count to less than 80% of pre-transfusion count but HPA antibodi ive.	or after mple, the ies were not
Investigation Results * Post transfusion purpura *Case Definition Check all that occurred af Alloantibodies in the p development of throu Thrombocytopenia (i.d Decrease in platelets Check all that apply: PTP is suspected, bur patient has a drop in tested or were negati Other signs and symptoms: (c Generalized:	a (PTP) fter cessation of transfusion : patient directed against HPA or other platelet specific antigen detected at mbocytopenia. e., decrease in platelets to less than 20% of pre-transfusion count). to levels between 20% and 80% of pre-transfusion count. tt laboratory findings and/or information are not sufficient. NOTE: For exar platelet count to less than 80% of pre-transfusion count but HPA antibodi ive. check all that apply) Chills/rigors	or after mple, the ies were not
Investigation Results * Post transfusion purpura *Case Definition Check all that occurred af Alloantibodies in the p development of thron Thrombocytopenia (i.d Decrease in platelets Check all that apply: PTP is suspected, bur patient has a drop in tested or were negati Other signs and symptoms: (c Generalized: Cardiovascular:	a (PTP) fter cessation of transfusion : patient directed against HPA or other platelet specific antigen detected at mbocytopenia. e., decrease in platelets to less than 20% of pre-transfusion count). to levels between 20% and 80% of pre-transfusion count. tt laboratory findings and/or information are not sufficient. NOTE: For exar platelet count to less than 80% of pre-transfusion count but HPA antibodi ive. check all that apply) Chills/rigors Fever Blood pressure decrease Shock Edema Flushing Jaundice Other rash Pruritus (itching) Urticaria (hiv	or after mple, the ies were not
Investigation Results * Post transfusion purpura *Case Definition Check all that occurred af Alloantibodies in the p development of thron Thrombocytopenia (i.d Decrease in platelets Check all that apply: PTP is suspected, bur patient has a drop in tested or were negati Other signs and symptoms: (c Generalized: Cardiovascular:	a (PTP) fter cessation of transfusion : patient directed against HPA or other platelet specific antigen detected at mbocytopenia. e., decrease in platelets to less than 20% of pre-transfusion count). to levels between 20% and 80% of pre-transfusion count. t laboratory findings and/or information are not sufficient. NOTE: For exar platelet count to less than 80% of pre-transfusion count but HPA antibodi ive. check all that apply) Chills/rigors Fever Blood pressure decrease Shock Edema Flushing Jaundice Other rash Pruritus (itching) Urticaria (hiv	or after mple, the ies were not
Investigation Results * Post transfusion purpura *Case Definition Check all that occurred af Alloantibodies in the p development of thron Thrombocytopenia (i.d Decrease in platelets Check all that apply: PTP is suspected, bur patient has a drop in tested or were negati Other signs and symptoms: (c Generalized: Cardiovascular: Cutaneous:	a (PTP) fter cessation of transfusion : patient directed against HPA or other platelet specific antigen detected at mbocytopenia. e., decrease in platelets to less than 20% of pre-transfusion count). to levels between 20% and 80% of pre-transfusion count. t laboratory findings and/or information are not sufficient. NOTE: For exar platelet count to less than 80% of pre-transfusion count but HPA antibodi ive. check all that apply) Chills/rigors Fever Blood pressure decrease Shock Edema Flushing Jaundice Other rash Pruritus (itching) Usseminated intravascular coagulation Hemoglobinemia	or after mple, the ies were not

NHSN NATIONAL HEALTHCARE SAFETY NETWORK			Form Approved OMB No. 0920-0666 Exp. Date: 01/31/25 www.cdc.gov/nhsn
Renal:	🗌 Hematuria 🔄 He	emoglobinuria 🛛 🗌 O	liguria
Respiratory:	☐ Bilateral infiltrates on chest x-ra	ay	Cough
Other: (specify)			
*Severity			
Did the patient receive or e	experience any of the following?		
No treatment require	ed 🗌 Symptom	atic treatment only	
Hospitalization, inlo	uding prolonged hospitalization	🗌 Life-threatenin	ig reaction
Disability and/or inc	apacitation 🛛 Congenita	al anomaly or birth defect(s) of the fetus
Other medically imp	ortant conditions	Unknown or no	ot stated
*Imputability			
Patient has no other	elationship between the transfusion a conditions to explain thrombocytope	nia.	
There are other pote likely cause.	ntial causes present that could expla	in thrombocytopenia, but t	ransfusion is the most
Alternate explanation	ns for thrombocytopenia are more like	ely, but transfusion cannot	be ruled out.
Evidence is clearly in	favor of a cause other than the trans	sfusion, but transfusion ca	nnot be excluded.
	vidence beyond reasonable doubt of		
The relationship betw	een the adverse reaction and the tra	Insfusion is unknown or no	ot stated.
Did the transfusion occur a	t your facility?	0	
When did the reaction occu	r in relation to the transfusion?		
Occurred 5-12 days	post-transfusion		
Occurred less than 5	or more than 12 days post-transfus	on	
Module-generated Design			
	efinition, severity, and imputability wi s in the corresponding investigation r		∍d in the NHSN
* Do you agree with the <u>ca</u> ^Please indicate your desi	ase definition designation?	☐ YES	
-	.		
* Do you agree with the <u>s</u> ^Please indicate your designed			□ NO
*Do you agree with the <u>in</u>		S YES	□ NO
^Please indicate your design	gnalion		
Patient Treatment			
-	nent for the transfusion reaction?	YES NO	
If yes, select treatment(s):	a turna of madiaction)		
Medication (Select th			ator 🗌 Diversition
] Antihistamines 🔲 Inotropes/Vas	·	
	nunoglobulin 🗌 Intravenous steroid		Antibiotics
Antithymocyte g	Jobulin 🗌 Cyclosporin 🗌	Other	

NATIONAL HEAI SAFETY NET	SN THCARE WORK							OMB No Exp. Da	rm Approved 5. 0920-0666 ate: 01/31/25 cdc.gov/nhsn
🗌 🗌 Volu	ume resuscitation (Intr	avenous colloid	s or ci	ystalloids)					
	piratory support <i>(Sele</i>	· · · ·	upport)						
] Mechanical ventilati	on 🗌 Nonir	nvasiv	e ventilation	I Oxygei	n			
	al replacement therap] Hemodialysis				no-Venous Herr	nofiltratio	on		
Phle	ebotomy								
Oth	er Specify:								
Outcome				· F	7				
*Outcome:	└ Death └ M ^ː Death: /	ajor or long-tern	n sequ	elae 🗌	∐ Minor or no se	equelae		t determ	nined
	recipient died, relation	/ ship of transfus	ion to	death:					
	Definite	·		Doubtful	🗌 Ruled Ou	ut 🗆	│Not de	etermine	d
	of death:								
Was ar	autopsy performed?	🗌 Yes	🗌 No						
Component	t Details								
*Was a parti reaction?	cular unit implicate	d in (i.e., respo		-	adverse	🗌 Ye	s 🔲 I	No 🗌] N/A
Transfusion		Amount	^Unit number (Required for*Unit expirationInfection and TRALI)Date/Time			*Blood group of unit			Implicate
Start and End Date/Time	*Component code (check system used)	transfused at reaction onset						р	d Unit?
	(check system used)							p	
Date/Time	(check system used)							p	
Date/Time	(check system used)						it	р	
Date/Time	(check system used) UNIT ISBT-128	reaction onset				of un	it □ A+		Unit?
Date/Time	(check system used) UNIT ISBT-128	reaction onset □ Entire unit □ Partial unit				of un	it □ A+ □ AB-	🗆 В-	Unit?
Date/Time	(check system used) UNIT ISBT-128	reaction onset □ Entire unit □ Partial unit				of un	it □ A+ □ AB-	□ B- □ AB+	Unit?
Date/Time	(check system used) UNIT I ISBT-128 Codabar	reaction onset				of un	it □ A+ □ AB- □ O+	□ B- □ AB+	Unit? Y
Date/Time	(check system used) UNIT ISBT-128 Codabar ISBT-128 ISBT-128	reaction onset				of un	it □ A+ □ AB- □ O+ □ A+	□ B- □ AB+ □ N/A	Unit?
Date/Time	(check system used) UNIT ISBT-128 Codabar ISBT-128 ISBT-128	reaction onset				of un	it □ A+ □ AB- □ O+ □ A+ □ A+ □ AB-	□ B- □ AB+ □ N/A □ B-	Unit? Y
Date/Time	(check system used) UNIT ISBT-128 Codabar ISBT-128 Codabar Codabar Codabar	reaction onset				of un	it □ A+ □ AB- □ O+ □ A+ □ A+ □ AB-	□ B- □ AB+ □ N/A □ B- □ AB+	Unit? Y
Date/Time	(check system used) UNIT ISBT-128 Codabar ISBT-128 Codabar Codabar Codabar	reaction onset				of un	it □ A+ □ AB- □ O+ □ A+ □ A+ □ AB-	□ B- □ AB+ □ N/A □ B- □ AB+	Unit? Y
Date/Time ^IMPLICATED /	(check system used) UNIT ISBT-128 Codabar ISBT-128 Codabar Codabar Codabar	reaction onset		I) 		of un	it □ A+ □ AB- □ O+ □ A+ □ A+ □ AB-	□ B- □ AB+ □ N/A □ B- □ AB+	Unit? Y
Date/Time ^IMPLICATED / / /	(check system used) UNIT ISBT-128 Codabar ISBT-128 Codabar Codabar Codabar	reaction onset		I) 		of un	it □ A+ □ AB- □ O+ □ A+ □ A+ □ AB-	□ B- □ AB+ □ N/A □ B- □ AB+	Unit? Y
Date/Time ^IMPLICATED /	(check system used) UNIT ISBT-128 Codabar ISBT-128 Codabar Codabar Codabar	reaction onset		I) 		of un	it □ A+ □ AB- □ O+ □ A+ □ A+ □ AB-	□ B- □ AB+ □ N/A □ B- □ AB+	Unit? Y
Date/Time ^IMPLICATED / / /	(check system used) UNIT ISBT-128 Codabar ISBT-128 Codabar Codabar Codabar	reaction onset		I) 		of un	it □ A+ □ AB- □ O+ □ A+ □ A+ □ AB-	□ B- □ AB+ □ N/A □ B- □ AB+	Unit? Y
Date/Time ^IMPLICATED / / /	(check system used) UNIT ISBT-128 Codabar ISBT-128 Codabar Codabar Codabar	reaction onset		I) 		of un	it □ A+ □ AB- □ O+ □ A+ □ A+ □ AB-	□ B- □ AB+ □ N/A □ B- □ AB+	Unit? Y

